TAM is an ER antagonist, mainly used in ER+ breast cancers through ER-dependent mechanism with definitive efficacy [9–11, 19, 26–31], and is thus much less efficacious in ER− breast cancers, such as TNBC [32]. Here, ESR1 is linked to breast carcinoma.